HK1167432A1 - Use of mgd-csf in a method of treatment of alzheimers disease mgd-csf - Google Patents
Use of mgd-csf in a method of treatment of alzheimers disease mgd-csfInfo
- Publication number
- HK1167432A1 HK1167432A1 HK12108108.8A HK12108108A HK1167432A1 HK 1167432 A1 HK1167432 A1 HK 1167432A1 HK 12108108 A HK12108108 A HK 12108108A HK 1167432 A1 HK1167432 A1 HK 1167432A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mgd
- csf
- treatment
- alzheimers disease
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
Abstract
The present invention relates to in vitro methods for stimulating, or increasing a population of, immune cells comprising using compositions which comprise a substantially pure polypeptide comprising a first amino acid sequence having at least about 70% homology to a sequence selected from SEQ. ID. NOs:7, 8, 9, and 11; or a biologically active fragment of any of these, wherein said polypeptide or fragment thereof can stimulate the proliferation and differentiation of granulocytes, monocytes, or dendritic cells; and to the use of these polypeptides in methods of treatment
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59056504P | 2004-07-22 | 2004-07-22 | |
US64760405P | 2005-01-27 | 2005-01-27 | |
US66493205P | 2005-03-24 | 2005-03-24 | |
US69901905P | 2005-07-14 | 2005-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1167432A1 true HK1167432A1 (en) | 2012-11-30 |
Family
ID=35448388
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07105690.5A HK1100223A1 (en) | 2004-07-22 | 2007-05-29 | Compositions and methods of use for mgd-csf in disease treatment |
HK12108108.8A HK1167432A1 (en) | 2004-07-22 | 2012-08-17 | Use of mgd-csf in a method of treatment of alzheimers disease mgd-csf |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07105690.5A HK1100223A1 (en) | 2004-07-22 | 2007-05-29 | Compositions and methods of use for mgd-csf in disease treatment |
Country Status (8)
Country | Link |
---|---|
US (4) | US20070264277A1 (en) |
EP (3) | EP2287310B1 (en) |
JP (4) | JP5435865B2 (en) |
AT (1) | ATE540973T1 (en) |
AU (1) | AU2005267062C1 (en) |
CA (1) | CA2574654C (en) |
HK (2) | HK1100223A1 (en) |
WO (1) | WO2006012451A2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7294704B2 (en) | 2003-08-15 | 2007-11-13 | Diadexus, Inc. | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk |
CA2589895A1 (en) * | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
US9060961B2 (en) * | 2006-11-09 | 2015-06-23 | University Of Washington | Molecules and methods for treatment and detection of cancer |
CN102083456B (en) * | 2008-03-25 | 2015-12-02 | 阿姆拉特斯治疗公司 | Neurodegenerative disorders |
WO2009137631A2 (en) * | 2008-05-07 | 2009-11-12 | Wintherix Llc | Methods for identifying compounds that affect expression of cancer-related protein isoforms |
US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
WO2011070024A1 (en) | 2009-12-10 | 2011-06-16 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
KR101647871B1 (en) | 2010-03-05 | 2016-08-11 | 에프. 호프만-라 로슈 아게 | Antibodies against human csf-1r and uses thereof |
KR101656548B1 (en) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | Antibodies against human csf-1r and uses thereof |
BR112012027994B1 (en) | 2010-05-04 | 2021-10-13 | Five Prime Therapeutics, Inc | ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF AN ANTIBODY |
US20110312506A1 (en) * | 2010-06-17 | 2011-12-22 | Dilyx Biotechnologies, LLC | Methods and kits for screening protein solubility |
CN104159921B (en) | 2011-12-15 | 2018-05-04 | 霍夫曼-拉罗奇有限公司 | Antibody for people CSF-1R and application thereof |
US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
CN107759690A (en) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | With the method for the Antybody therapy symptom for combining the acceptor of colony stimulating factor 1 (CSF1R) |
EP2931293B1 (en) | 2012-12-12 | 2019-02-20 | University Of Virginia Patent Foundation | Compositions and methods for regulating erythropoiesis |
AR095882A1 (en) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R WITH A TLR9 AGONIST |
AR097584A1 (en) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1 |
US10683477B2 (en) | 2014-02-25 | 2020-06-16 | Corning Incorporated | Spheroid-producing device, method for recovering spheroids, and method for producing spheroids |
EP3152557A4 (en) | 2014-06-09 | 2017-12-13 | Biometry Inc. | Low cost test strip and method to measure analyte |
US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
KR20230086809A (en) | 2014-06-23 | 2023-06-15 | 파이브 프라임 테라퓨틱스, 인크. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
US20160060597A1 (en) * | 2014-08-28 | 2016-03-03 | The University Of Maryland, Baltimore | Functional myelination of neurons |
WO2016069727A1 (en) | 2014-10-29 | 2016-05-06 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
JP2017535794A (en) * | 2014-11-03 | 2017-11-30 | バイオインセプト、エルエルシー | PIF binding as a marker for immune dysregulation |
SG11201704792UA (en) | 2014-12-22 | 2017-07-28 | Five Prime Therapeutics Inc | Anti-csf1r antibodies for treating pvns |
CN107709365A (en) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | Cancer combination treatment |
CN109715067B (en) | 2016-07-19 | 2022-05-17 | 生物统计股份有限公司 | Method and system for measuring analytes using batch calibratable test strips |
EP3504239B1 (en) | 2016-08-25 | 2024-05-29 | F. Hoffmann-La Roche AG | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
EP3558360A1 (en) | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
WO2018133937A1 (en) * | 2017-01-19 | 2018-07-26 | Biontech Ag | Engineered cells for inducing tolerance |
CN107130009A (en) * | 2017-07-13 | 2017-09-05 | 华南理工大学 | A kind of novel polypeptide with immunocompetence and anti-erythrocyte hemolytic activity and preparation method thereof |
JP2020535119A (en) | 2017-09-13 | 2020-12-03 | ファイヴ プライム セラピューティクス インク | Combination therapy of anti-CSF1R and anti-PD-1 antibody for pancreatic cancer |
CN109456989B (en) * | 2018-10-31 | 2022-03-29 | 陕西慧康生物科技有限责任公司 | Construction method of vector for improving secretion expression of pichia pastoris |
CN109593126B (en) * | 2018-11-28 | 2019-11-22 | 山西锦波生物医药股份有限公司 | Polypeptide, its production method and purposes |
CN109468361B (en) * | 2018-11-29 | 2021-11-02 | 电子科技大学 | Method for measuring mononuclear/macrophage capacity of fish natural killer cell killing bacterial infection |
CN109596839A (en) * | 2018-12-25 | 2019-04-09 | 广州万孚生物技术股份有限公司 | People and peptide element fast quantitative measurement method for detecting and kit |
SG11202107606VA (en) * | 2019-01-15 | 2021-08-30 | Inst Nat Sante Rech Med | Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy |
CN111150841B (en) * | 2019-12-31 | 2023-08-15 | 优锐生物医药科技(深圳)有限公司 | Active immune regulation particle and preparation method and application thereof |
CN114113602B (en) * | 2020-08-28 | 2024-07-02 | 香港城市大学深圳研究院 | Immunoglobulin-related coagulation factor X as biomarker for acute myocardial infarction |
US20240335562A1 (en) * | 2021-08-04 | 2024-10-10 | Alpine Biotherapeutics Corporation | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4433092A (en) | 1981-03-09 | 1984-02-21 | Champion Spark Plug Company | Green ceramic of lead-free glass, conductive carbon, silicone resin and AlPO4, useful, after firing, as an electrical resistor |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
CA1255586A (en) | 1984-07-24 | 1989-06-13 | Hendrik M. Geysen | Method of determining mimotopes |
JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
WO1987001130A1 (en) | 1985-08-15 | 1987-02-26 | Stauffer Chemical Company | Tryptophan producing microorganism |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5831036A (en) * | 1987-05-04 | 1998-11-03 | Dana Farber Cancer Institute | Soluble fragments of human intercellular adhesion molecule-1 |
DE3852823T2 (en) | 1987-09-11 | 1995-05-24 | Hughes Howard Med Inst | TRANSDUCTION-CHANGED FIBROBLASTS AND THEIR USE. |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
ATE135370T1 (en) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
JPH0525056A (en) * | 1989-07-27 | 1993-02-02 | Max Planck Inst Fuer Saikaiatorii | Adjustment of nerve growth factor synthesis in central nervous system |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
ES2120949T4 (en) | 1990-06-28 | 2011-12-29 | Sanofi-Aventis Deutschland Gmbh 50% | FUSION PROTEINS WITH LOTS OF IMMUNOGLOBULINS, THEIR PREPARATION AND EMPLOYMENT. |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5399349A (en) | 1992-02-06 | 1995-03-21 | Paunescu; Calin | Treatment of acne |
US5480971A (en) | 1993-06-17 | 1996-01-02 | Houghten Pharmaceuticals, Inc. | Peralkylated oligopeptide mixtures |
US5620889A (en) | 1993-10-14 | 1997-04-15 | Immunex Corporation | Human anti-Fas IgG1 monoclonal antibodies |
US5643786A (en) * | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
US6395964B1 (en) | 1995-10-24 | 2002-05-28 | The Texas A&M University System | Oral immunization with transgenic plants |
EP1469883A2 (en) | 1998-02-19 | 2004-10-27 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
US20040001826A1 (en) * | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
US20040048249A1 (en) * | 2000-01-21 | 2004-03-11 | Tang Y. Tom | Novel nucleic acids and secreted polypeptides |
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
CA2428216A1 (en) | 2000-12-13 | 2002-06-20 | Incyte Genomics, Inc. | Secreted proteins |
AU2002255478A1 (en) * | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
EP1556490A4 (en) * | 2002-10-22 | 2006-04-05 | Nuvelo Inc | Novel nucleic acids and polypeptides |
-
2005
- 2005-07-21 AT AT05791762T patent/ATE540973T1/en active
- 2005-07-21 WO PCT/US2005/025941 patent/WO2006012451A2/en active Application Filing
- 2005-07-21 CA CA2574654A patent/CA2574654C/en not_active Expired - Fee Related
- 2005-07-21 US US11/632,319 patent/US20070264277A1/en not_active Abandoned
- 2005-07-21 JP JP2007522769A patent/JP5435865B2/en not_active Expired - Fee Related
- 2005-07-21 EP EP20100179665 patent/EP2287310B1/en not_active Not-in-force
- 2005-07-21 AU AU2005267062A patent/AU2005267062C1/en not_active Ceased
- 2005-07-21 EP EP05791762A patent/EP1778842B8/en not_active Ceased
- 2005-07-21 EP EP12150386.6A patent/EP2479277B1/en not_active Not-in-force
-
2007
- 2007-05-29 HK HK07105690.5A patent/HK1100223A1/en not_active IP Right Cessation
-
2009
- 2009-02-12 US US12/370,559 patent/US8178109B2/en not_active Expired - Fee Related
-
2012
- 2012-04-13 US US13/446,254 patent/US8575312B2/en not_active Expired - Fee Related
- 2012-08-17 HK HK12108108.8A patent/HK1167432A1/en not_active IP Right Cessation
-
2013
- 2013-10-08 US US14/048,834 patent/US20140170145A1/en not_active Abandoned
- 2013-10-31 JP JP2013226693A patent/JP5815638B2/en not_active Expired - Fee Related
-
2015
- 2015-02-18 JP JP2015029580A patent/JP2015133970A/en active Pending
-
2016
- 2016-05-24 JP JP2016103092A patent/JP2016146850A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2014034577A (en) | 2014-02-24 |
JP2015133970A (en) | 2015-07-27 |
CA2574654C (en) | 2014-02-18 |
AU2005267062B2 (en) | 2012-05-17 |
HK1100223A1 (en) | 2007-09-14 |
WO2006012451A2 (en) | 2006-02-02 |
JP2016146850A (en) | 2016-08-18 |
AU2005267062C1 (en) | 2013-01-17 |
AU2005267062A1 (en) | 2006-02-02 |
JP5815638B2 (en) | 2015-11-17 |
EP1778842B1 (en) | 2012-01-11 |
ATE540973T1 (en) | 2012-01-15 |
EP2287310A1 (en) | 2011-02-23 |
US20070264277A1 (en) | 2007-11-15 |
EP2479277A3 (en) | 2012-08-22 |
EP2479277B1 (en) | 2015-09-02 |
CA2574654A1 (en) | 2006-02-02 |
US20110003384A1 (en) | 2011-01-06 |
US8178109B2 (en) | 2012-05-15 |
WO2006012451A3 (en) | 2006-03-30 |
US20120258071A1 (en) | 2012-10-11 |
US8575312B2 (en) | 2013-11-05 |
EP2479277A2 (en) | 2012-07-25 |
US20140170145A1 (en) | 2014-06-19 |
JP5435865B2 (en) | 2014-03-05 |
EP2287310B1 (en) | 2015-05-06 |
EP1778842A2 (en) | 2007-05-02 |
JP2008507283A (en) | 2008-03-13 |
EP1778842B8 (en) | 2012-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1167432A1 (en) | Use of mgd-csf in a method of treatment of alzheimers disease mgd-csf | |
DK2864360T3 (en) | TARGETED THERAPY | |
MX2008009493A (en) | Novel peptide and use thereof. | |
IN2015DN02553A (en) | ||
JP2012515778A5 (en) | ||
MX348154B (en) | IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF. | |
WO1999046366A8 (en) | Uses for humane non-autologous mesenchymal stem cells | |
NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
RU2009137017A (en) | COMPOSITIONS AND METHODS OF APPLICATION OF ANGIOPOETIN-LIKE PROTEIN 4 | |
AU9084601A (en) | G-csf analog compositions and methods | |
TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
RU2432360C2 (en) | Epo version exhibiting increased receptor binding affinity and lower antigen potential, dna coding such epo version, recombinant expression vector containing such dna, host cell transformed or transfected by such vector, method for producing such epo version and pharmaceutical composition containing such epo version | |
ATE500847T1 (en) | PEGYLATED G-CSF POLYPEPTIDES AND PRODUCTION METHOD THEREOF | |
NZ279963A (en) | Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946 | |
JP2006506942A5 (en) | ||
HK1129128A1 (en) | Recombinant human interferon-like proteins | |
CA2461443A1 (en) | Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use | |
UA91820C2 (en) | Therapeutic uses of chemokine variants | |
RU2007115411A (en) | HSP60 PEPTIDES AND THEIR APL-DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | |
MXPA05008704A (en) | Fusion proteins of interferon alpha muteins with improved properties. | |
WO2006028561A3 (en) | Novel purified fabi polypeptides from fransicella tularensis | |
WO2003102162A3 (en) | Novel tolerogenic dendritic cells and therapeutic uses therefor | |
EP1796707A4 (en) | Peptides that selectively home to heart vasculature and related conjugates and methods | |
ATE356205T1 (en) | DAIRY-ASSOCIATED BOVINE IMMUNOTROPIC PROTEIN (CD14), GENE ENCODING AND USE FOR ACTIVATION OF B CELLS | |
MXPA03007002A (en) | Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190719 |